Bumetanide in Patients With Alzheimer's Disease
About this study
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets. Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease. Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Condition
- Alzheimer Disease
- Tested
- Bumetanide, Placebo
- Sponsor
- Stanford University
Who can join
- Age
- 50 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 50 years
- Maximum age: 85 years
- Study condition: Alzheimer Disease
- Mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Alzheimer's disease medications are planned to remain stable throughout.
- Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI.
Exclusion 5
- Clinically significant abnormalities in screening laboratory tests
- Chronic liver disease
- Renal insufficiency
- Poorly managed hypertension
- Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
Where
1 site, 1 recruiting
Stanford University
Stanford, California, United States
Contact
-
Mina L Kim
(650) 387-1559 minakim@stanford.edu
Potential match only. Final eligibility is determined by the study team.